Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ProQR Therapeutics N.V. - Ordinary Shares (NQ:PRQR)

1.550 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.550
Bid (Size) 1.400 (2)
Ask (Size) 1.710 (31)
Prev. Close 1.550
Today's Range 1.550 - 1.550
52wk Range 1.070 - 4.620
Shares Outstanding 80,817,079
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ProQR Announces First Quarter 2025 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire

Performance

YTD
-43.4%
-43.4%
1 Month
+37.2%
+37.2%
3 Month
-35.4%
-35.4%
6 Month
-56.6%
-56.6%
1 Year
-22.5%
-22.5%

More News

Read More
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Year End 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
This Ralph Lauren Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
ProQR Announces Third Quarter 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
From ProQR Therapeutics N.V.
Via GlobeNewswire
CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire
PRQR Stock Earnings: ProQR Therapeutics Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
ProQR Announces Second Quarter 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces First Quarter 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire

Frequently Asked Questions

Is ProQR Therapeutics N.V. - Ordinary Shares publicly traded?
Yes, ProQR Therapeutics N.V. - Ordinary Shares is publicly traded.
What exchange does ProQR Therapeutics N.V. - Ordinary Shares trade on?
ProQR Therapeutics N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for ProQR Therapeutics N.V. - Ordinary Shares?
The ticker symbol for ProQR Therapeutics N.V. - Ordinary Shares is PRQR on the Nasdaq Stock Market
What is the current price of ProQR Therapeutics N.V. - Ordinary Shares?
The current price of ProQR Therapeutics N.V. - Ordinary Shares is 1.550
When was ProQR Therapeutics N.V. - Ordinary Shares last traded?
The last trade of ProQR Therapeutics N.V. - Ordinary Shares was at 05/08/25 04:00 PM ET
What is the market capitalization of ProQR Therapeutics N.V. - Ordinary Shares?
The market capitalization of ProQR Therapeutics N.V. - Ordinary Shares is 125.27M
How many shares of ProQR Therapeutics N.V. - Ordinary Shares are outstanding?
ProQR Therapeutics N.V. - Ordinary Shares has 125M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.